rxstat › Drug prices › Mepolizumab

Mepolizumab (Nucala) price in Canada

No current shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Mepolizumab 100 mg/ml solution costs about $2206.64 per billed unit (often a pen or vial) on public drug plan price lists in Alberta, before the pharmacy's dispensing fee.

Mepolizumab has no current shortage reported in Canada. It has been in shortage before; the history is below.

Price by province

Strength and formABSKNBNS
100 mg/ml Solution$2206.64/unit$22.07/unit$2206.64/syringe$2301.24/unit
40 mg/0.4ml Solution$951.15/unitnot covered–––
100 mg/vial Powder For Solution–$20.59/unit––
Plan coverageCoveredSpecial approvalSpecial approvalSpecial approval

Lowest price per unit among each province's covered products, with the brand price where it is notably higher. A dash means the province does not list it. Provinces bill some products (injectables especially) per mL and others per pen or vial, so compare prices with the same unit.

Detailed price and coverage in your province:

What you'll pay at the pharmacy

These are the prices public drug plans list for the drug itself. At the counter, pharmacies add a dispensing fee and in some provinces a markup, so paying cash costs more, and for cheap generics the fee is often more than the drug. If you have a public or private plan, your share depends on its deductible and co-pay.

Listed products by province

Alberta: 3 products
  • Nucala 40 mg/0.4ml Solution · GSK
    DIN 02530821 · $951.15/unit · Not covered
  • Nucala 100 mg/ml Solution · GSK
    DIN 02492989 · $2206.64/unit · Covered
  • Nucala 100 mg/ml Solution · GSK
    DIN 02492997 · $2206.64/unit · Covered
Saskatchewan: 3 products
  • Nucala 100 mg/vial Powder For Solution · GSK
    DIN 02449781 · $20.59/unit · Special approval
  • Nucala 100 mg/ml Solution · GSK
    DIN 02492989 · $22.07/unit · Special approval
  • Nucala 100 mg/ml Solution · GSK
    DIN 02492997 · $22.07/unit · Special approval
New Brunswick: 2 products
  • Nucala 100 mg/ml Solution · GSK
    DIN 02492989 · $2206.64/syringe · Special approval
  • Nucala 100 mg/ml Solution · GSK
    DIN 02492997 · $2206.64/syringe · Special approval
Nova Scotia: 2 products
  • Nucala 100 mg/ml Solution · GSK
    DIN 02492989 · $2301.24/unit · Special approval
  • Nucala 100 mg/ml Solution · GSK
    DIN 02492997 · $2301.24/unit · Special approval

Price sources: Alberta Drug Benefit List and Alberta Blue Cross price list (Nov 1, 2026) · Saskatchewan Drug Plan Formulary (Nov 1, 2026) · New Brunswick Drug Plans Formulary (Nov 1, 2026) · Nova Scotia Pharmacare Formulary (Nov 1, 2026). Other provinces and territories will be added as their public price lists are brought in.

Shortage status

Products affected
0 / 3
Reports on file
4

Reports by product

The DIN is printed on your prescription label.

Discontinued
NUCALA
100MG · POWDER FOR SOLUTION · GLAXOSMITHKLINE INC
DIN 02449781
Resolved
NUCALA
100MG · SOLUTION · GLAXOSMITHKLINE INC
DIN 02492997 · ended Aug 3, 2021 · Disruption of the manufacture of the drug.
Resolved
NUCALA
100MG · SOLUTION · GLAXOSMITHKLINE INC
DIN 02492989 · ended Jul 23, 2021 · Disruption of the manufacture of the drug.
Resolved
NUCALA
100MG · SOLUTION · GLAXOSMITHKLINE INC
DIN 02492989 · ended Jan 20, 2021 · Disruption of the manufacture of the drug.

What's happening

There are no active shortage reports for Mepolizumab. Health Canada has 4 historical reports on file for this drug, so supply has been disrupted before; the change log below shows the history.

Mepolizumab is classified under “OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES” (ATC R03DX).

Recent changes

Common questions

How much does Mepolizumab cost in Canada?

Mepolizumab 100 mg/ml solution costs about $2206.64 per billed unit (often a pen or vial) on public drug plan price lists in Alberta, before the pharmacy's dispensing fee.

Is Mepolizumab covered by provincial drug plans?

On the public plans' own lists: Alberta: covered; Saskatchewan: special approval; New Brunswick: special approval; Nova Scotia: special approval. "Special approval" means the plan covers it only for some patients, on a request from the prescriber. "Price list" means the province publishes its price but not its coverage.

When will Mepolizumab be back in stock in Canada?

Mepolizumab has no active shortage; supply is normal per Health Canada reports.

Why is Mepolizumab in shortage?

It isn't currently. Past reports and their reasons are listed above.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Related drugs (other systemic drugs for obstructive airway diseases)

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.